KRAS G12D-targeted TCR-T cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for KRAS G12D-targeted TCR-T cell therapy, covering 2026-03-09 to 2026-03-09. Get the full timeline:
Most recent: Clinical Trial Update: Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors [Phase 1]